News

BMJ2d
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by ...
Rheumatology, Med Klinik I, Charité, Campus Benjamin Franklin, Berlin, Germany ...
BMJ3d
ASAS consensus definition of early axial spondyloarthritis
Objectives To develop a consensual definition for the term ‘early axial spondyloarthritis—axSpA’—and ‘early peripheral spondyloarthritis—pSpA’. Methods The ASAS (Assessment of SpondyloArthritis ...
BMJ3d
Activation of acid-sensing ion channel 3 by lysophosphatidylcholine 16:0 mediates psychological stress-induced fibromyalgia-like pain
Objectives Fibromyalgia is commonly considered a stress-related chronic pain disorder, and daily stressors are known triggers. However, the relation between stress and pain development remains poorly ...
BMJ1mon
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of ...
Objectives To inform the 2019 update of the European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA). Methods A systematic literature research (SLR) ...
BMJ4mon
Evidence that autoantibody production may be driven by acute Epstein-Barr virus infection in Sjögren’s disease
Objectives Sjögren’s disease (SD) is an autoimmune disease affecting the exocrine glands that is associated with autoantibodies against Ro60/SS-A, anti-Ro52/TRIM21, La/SS-B and others. We examined the ...
BMJ5mon
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a ...
Background Targeted therapies have been associated with potential risk of malignancy, which is a common concern in daily rheumatology practice in patients with inflammatory arthritis (IA) and a ...
BMJ6mon
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Background There is considerable practice variation in labelling, diagnosis and treatment of adults with sterile bone inflammation. We developed a expert consensus recommendations on the disease ...
BMJ6mon
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
‘Poly-refractory’ disease affects 2.7% of patients with rheumatoid arthritis (RA) who have failed different groups of biologic disease-modifying antirheumatic drugs (b-DMARDS) and targeted synthetic ...
BMJ6mon
Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium
Objectives To identify phenotype clusters and their trajectories in psoriatic arthritis (PsA) and examine the association of the clusters with treatment response in a real-world setting. Methods In ...
BMJ6mon
Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis
3 Centre de Recherche en Epidémiologie et Statistiques (CRESS), Unité Inserm 1153, Université Paris Cité, Paris, France ...
BMJ7mon
Cure as a treatment target in rheumatoid arthritis and systemic sclerosis—achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration
The past 25 years have witnessed a remarkable revolution in outcomes for patients living with rheumatoid arthritis (RA). Historically, uncontrolled joint inflammation was commonplace leading to ...
BMJ7mon
Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis ...
Objectives Belimumab is a putative disease-modifying agent in systemic lupus erythematosus (SLE), yet the molecular underpinnings of its effects and the ability to predict early clinical response ...